Literature DB >> 22334030

Largazole: from discovery to broad-spectrum therapy.

Jiyong Hong1, Hendrik Luesch.   

Abstract

The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chemical scaffold and potently inhibits class I histone deacetylases (HDACs). Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells. The intriguing structure and biological activity of largazole have attracted strong interest from the synthetic chemistry community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic. This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure-activity relationships, HDAC8-largazole thiol crystal structure, and biological studies, including in vivo anticancer and osteogenic activities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334030      PMCID: PMC4777309          DOI: 10.1039/c2np00066k

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   13.423


  43 in total

1.  Synthesis and biological activity of largazole and derivatives.

Authors:  Tobias Seiser; Faustin Kamena; Nicolai Cramer
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

2.  Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.

Authors:  Hanae Benelkebir; Sabrina Marie; Annette L Hayden; Jason Lyle; Paul M Loadman; Simon J Crabb; Graham Packham; A Ganesan
Journal:  Bioorg Med Chem       Date:  2011-02-17       Impact factor: 3.641

3.  Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

Authors:  H Luesch; R E Moore; V J Paul; S L Mooberry; T H Corbett
Journal:  J Nat Prod       Date:  2001-07       Impact factor: 4.050

4.  In Vitro and In Vivo Osteogenic Activity of Largazole.

Authors:  Su-Ui Lee; Han Bok Kwak; Sung-Hee Pi; Hyung-Keun You; Seong Rim Byeon; Yongcheng Ying; Hendrik Luesch; Jiyong Hong; Seong Hwan Kim
Journal:  ACS Med Chem Lett       Date:  2011-03-10       Impact factor: 4.345

5.  Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.

Authors:  Yanxia Liu; Lilibeth A Salvador; Seongrim Byeon; Yongcheng Ying; Jason C Kwan; Brian K Law; Jiyong Hong; Hendrik Luesch
Journal:  J Pharmacol Exp Ther       Date:  2010-08-25       Impact factor: 4.030

6.  Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells.

Authors:  J Schwaller; T Pabst; H P Koeffler; G Niklaus; P Loetscher; M F Fey; A Tobler
Journal:  Leukemia       Date:  1997-01       Impact factor: 11.528

7.  Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.

Authors:  José A Souto; Esther Vaz; Ilaria Lepore; Ann-Christin Pöppler; Gianluigi Franci; Rosana Alvarez; Lucia Altucci; Angel R de Lera
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

8.  Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors.

Authors:  Marina Naldi; Natalia Calonghi; Lanfranco Masotti; Carola Parolin; Sergio Valente; Antonello Mai; Vincenza Andrisano
Journal:  Proteomics       Date:  2009-12       Impact factor: 3.984

9.  Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.

Authors:  Yongcheng Ying; Kanchan Taori; Hyoungsu Kim; Jiyong Hong; Hendrik Luesch
Journal:  J Am Chem Soc       Date:  2008-05-29       Impact factor: 15.419

10.  Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.

Authors:  Albert A Bowers; Thomas J Greshock; Nathan West; Guillermina Estiu; Stuart L Schreiber; Olaf Wiest; Robert M Williams; James E Bradner
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

View more
  43 in total

1.  Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.

Authors:  Fatma H Al-Awadhi; Lilibeth A Salvador-Reyes; Lobna A Elsadek; Ranjala Ratnayake; Qi-Yin Chen; Hendrik Luesch
Journal:  ACS Chem Neurosci       Date:  2020-06-19       Impact factor: 4.418

Review 2.  Discovery and mechanism of natural products as modulators of histone acetylation.

Authors:  Lilibeth A Salvador; Hendrik Luesch
Journal:  Curr Drug Targets       Date:  2012-07       Impact factor: 3.465

3.  Apratoxin H and apratoxin A sulfoxide from the Red Sea cyanobacterium Moorea producens.

Authors:  Christopher C Thornburg; Elise S Cowley; Justyna Sikorska; Lamiaa A Shaala; Jane E Ishmael; Diaa T A Youssef; Kerry L McPhail
Journal:  J Nat Prod       Date:  2013-09-09       Impact factor: 4.050

Review 4.  An overview of naturally occurring histone deacetylase inhibitors.

Authors:  Bumki Kim; Jiyong Hong
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 5.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

Review 6.  Advances in exploring the therapeutic potential of marine natural products.

Authors:  Xiao Liang; Danmeng Luo; Hendrik Luesch
Journal:  Pharmacol Res       Date:  2019-07-25       Impact factor: 7.658

7.  Seaweed extracts and unsaturated fatty acid constituents from the green alga Ulva lactuca as activators of the cytoprotective Nrf2-ARE pathway.

Authors:  Rui Wang; Valerie J Paul; Hendrik Luesch
Journal:  Free Radic Biol Med       Date:  2013-01-04       Impact factor: 7.376

8.  Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.

Authors:  Lilibeth A Salvador; Heekwang Park; Fatma H Al-Awadhi; Yanxia Liu; Bumki Kim; Sabrina L Zeller; Qi-Yin Chen; Jiyong Hong; Hendrik Luesch
Journal:  ACS Med Chem Lett       Date:  2014-07-07       Impact factor: 4.345

9.  Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole.

Authors:  Dane J Clausen; William B Smith; Brandon E Haines; Olaf Wiest; James E Bradner; Robert M Williams
Journal:  Bioorg Med Chem       Date:  2015-03-31       Impact factor: 3.641

10.  Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis.

Authors:  Danmeng Luo; Hendrik Luesch
Journal:  ACS Med Chem Lett       Date:  2020-03-04       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.